BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lurje I, Hammerich L, Tacke F. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci 2020;21:E7378. [PMID: 33036244 DOI: 10.3390/ijms21197378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu T, Li C, Xiang C, Gong Y, Peng W, Chen C, Gas P. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients. BioMed Research International 2022;2022:1-14. [DOI: 10.1155/2022/7823191] [Reference Citation Analysis]
2 Bocchino M, Zanotta S, Capitelli L, Galati D. Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis. Front Immunol 2021;12:664109. [PMID: 33995394 DOI: 10.3389/fimmu.2021.664109] [Reference Citation Analysis]
3 Li S, Huang J, Yang F, Zeng H, Tong Y, Li K. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2021;11:11078. [PMID: 34040099 DOI: 10.1038/s41598-021-90507-w] [Reference Citation Analysis]
4 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
6 Yasuma T, Gabazza EC. Chronic Fibrosis and Its Progression to Cancer. Int J Mol Sci 2022;23:3924. [PMID: 35409286 DOI: 10.3390/ijms23073924] [Reference Citation Analysis]
7 Cazzetta V, Franzese S, Carenza C, Della Bella S, Mikulak J, Mavilio D. Natural Killer-Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy. Cancers (Basel) 2021;13:2184. [PMID: 34062821 DOI: 10.3390/cancers13092184] [Reference Citation Analysis]
8 Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. J Hepatol 2022:S0168-8278(22)00375-0. [PMID: 35750137 DOI: 10.1016/j.jhep.2022.06.012] [Reference Citation Analysis]
9 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
12 Wang Y, Han J, Zhou H, Ai S, Wan D, Zhuo Z. A Prognosis Marker Dynein Cytoplasmic 1 Heavy Chain 1 Correlates with EMT and Immune Signature in Liver Hepatocellular Carcinoma by Bioinformatics and Experimental Analysis. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/6304859] [Reference Citation Analysis]
13 Mo C, Xie S, Zeng T, Lai Y, Huang S, Zhou C, Yan W, Huang S, Gao L, Lv Z. Ginsenoside-Rg1 acts as an IDO1 inhibitor, protects against liver fibrosis via alleviating IDO1-mediated the inhibition of DCs maturation. Phytomedicine 2021;84:153524. [PMID: 33667840 DOI: 10.1016/j.phymed.2021.153524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zheng X, Jin W, Wang S, Ding H. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:729705. [PMID: 34566989 DOI: 10.3389/fimmu.2021.729705] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zhu H, Xiao H, Lu G, Fang S, Akhlaq M. Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/9722458] [Reference Citation Analysis]
17 Zhang R, Huang X, Jiang Y, Wang J, Chen S. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2020;2020:8887574. [PMID: 33381477 DOI: 10.1155/2020/8887574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Qiu Y, Li H, Xie J, Qiao X, Wu J. Identification of ABCC5 Among ATP-Binding Cassette Transporter Family as a New Biomarker for Hepatocellular Carcinoma Based on Bioinformatics Analysis. Int J Gen Med 2021;14:7235-46. [PMID: 34737618 DOI: 10.2147/IJGM.S333904] [Reference Citation Analysis]
19 Zhou Z, Lin L, An Y, Zhan M, Chen Y, Cai M, Zhu X, Lu L, Zhu K. The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:529-43. [PMID: 34136421 DOI: 10.2147/JHC.S301375] [Reference Citation Analysis]
20 Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life (Basel) 2021;11:1355. [PMID: 34947886 DOI: 10.3390/life11121355] [Reference Citation Analysis]
21 von Bülow V, Lichtenberger J, Grevelding CG, Falcone FH, Roeb E, Roderfeld M. Does Schistosoma Mansoni Facilitate Carcinogenesis? Cells 2021;10:1982. [DOI: 10.3390/cells10081982] [Reference Citation Analysis]